
Offer Date | Jul 14 - Jul 16, 2025 |
Offer Price | ₹ 540-570 |
Lot Size | 26 |
Please login to Apply IPO
Offer Date: Jul 14, 2025 - Jul 16, 2025
Exp. Premium: 98-100 (17.19%)
₹ 14820 /26 Shares
Pre-Apply*Expected Premium provided in this app is derived from market rumors. It is not a guaranteed indicator of the actual listing price and should be interpreted with caution.
14 Jul, 2025
Open Date16 Jul, 2025
Close Date17 Jul, 2025
Allotment Date21 Jul, 2025
Listing DateIssue Price
₹540-570 per equity shareFace Value
₹2 Per Equity ShareListing at Group
BSE, NSERegistrar
Kfin Technologies LimitedMarket Lot
Retail : 26 Shares (₹14,820/-)Lead Manager
Jm Financial LimitedIssue Size
OFS : 5,95,61,404 shares(aggregating up to ₹3395.00 Cr)Retail Portion
35% (Number of Retail Applications: 7,99,840 Approx),Subscription
N/A times
Anthem Biosciences IPO is a book-built issue of ₹3395 crores, The total issue size is ₹3395 crores. The IPO of Anthem Biosciences is priced at ₹540-570 per equity share, which has a face value of ₹2 Per Equity Share each, IPO bidding starts from Jul 14, 2025 and ends on Jul 16, 2025. The allotment for Anthem Biosciences IPO will be finalized on Jul 17, 2025. Anthem Biosciences IPO will be listed on BSE, NSE, with a tentative listing date fixed as Jul 21, 2025. The company shall list its equity shares on the BSE, NSE. Kfin Technologies Limited is the registrar of the issue.
Retail investors can bid for a minimum of 26 shares, extendable to 14,820. S-HNIs will be able to bid for 364 shares at ₹2,07,480, while B-HNIs can also apply for a bid of 1,768 shares at ₹10,07,760. The book-running lead manager for the IPO is/are Jm Financial Limited , Citigroup Global Markets India Private Limited , J.P. Morgan India Private Limited , Nomura Financial Advisory And Securities (India) Pvt Ltd .
an Offer for Sale (OFS) of 5,95,61,404 shares to mop up ₹3395 crore.
The Anthem Biosciences IPO sets its price band at 540-570 for each share. A single application for Anthem Biosciences Limited IPO must contain at least 26 shares. Sentiment investors need to invest a minimum of 26 through their retail account. For investors to prevent oversubscription issues, they should submit bids at the cutoff price, which estimates about ₹14,820 In order to participate in the sNII, investors must purchase at least 14 lots of 364 shares for ₹2,07,480, while the bNII requires 68 lots of 1,768 shares for an investment of ₹10,07,760.
EPS Pre IPO
₹8.07/-EPS Post IPO
₹8.07/-P/E Pre IPO
70.62P/E Post IPO
70.62ROE
20.82%ROCE
26.88%Debt/Equity
0.05RoNW
20.82%PAT Margin
23.38%Price to Book Value
13.2331-Mar-25 | 31-Mar-24 | 31-Mar-23 | |
---|---|---|---|
Assets | 2,807.58 | 2,398.11 | 2,014.46 |
Revenue | 1,930.29 | 1,483.07 | 1,133.99 |
Profit After Tax | 451.26 | 367.31 | 385.19 |
Net Worth | 2,409.86 | 1,924.66 | 1,740.67 |
Reserves & Surplus | 2,298.05 | 1,815.39 | 1,628.88 |
Total Borrowing | 108.95 | 232.53 | 125.06 |
Founded in 2006, Anthem Biosciences Limited is a technology and innovation-led Contract Research, Development, and Manufacturing Organization (CRDMO) with vertically integrated operations covering drug discovery, development, and manufacturing activities.
The company caters to varied customers such as innovative, early-stage biotech companies and big pharma companies globally.The company produces niche fermentation-based APIs, such as probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.For the half-year ended September 30, 2024, the company was involved in the production of active pharmaceutical ingredients (API) and intermediates for ten commercial molecules, all of which have been funded since discovery.
The company had 196 projects as of September 30 2024: 170 discovery projects (284 synthesized molecules), 132 early phase projects, 16 late phase projects (10 late phase molecules), and 13 commercial manufacturing projects (API and intermediates for 10 commercialized molecules).
As of March 31, 2024, and September 30, 2024, the company had more than 425 and 550 customers for our CRDMO and specialty ingredients business, distributed across more than 44 countries, including Europe, Japan, and the U.S.As of March 31, 2024, the company had more than 150 customers, ranging from small biotech to big pharma.As of 30 September 2024, the company has one patent in India, seven foreign, and 24 pending foreign patent applications, including process patents for glycolipid synthesis and GLP-1 analogues.
As of 30 September 2024, the company has 600 employees, including medicinal chemists, microbiologists, molecular biologists, biochemists, specialists in different in-vivo non-clinical research and chemical engineers.
Fastest Indian CRDMO to cross ₹10,000 million revenue in 14 years.
Offers integrated CRDMO services across both small molecules and biologics.
Serves diverse global clients including Bayer AG and emerging biotech.
Operating India’s largest fermentation capacity of 142 kL as of Sep 2024
CRDMO services contributed 81.13% revenue; demand decline may hurt.
Top 10 customers contributed 76.75% revenue; loss impacts business.
Regulatory non-compliance may disrupt exports, approvals, and customer confidence.
Underused capacity and poor forecasts could hurt future performance.
P/B Ratio | P/E Ratio | RoNW | Net Worth | |
---|---|---|---|---|
Anthem Biosciences | N/A | N/A | 20.8% | 1844 |
Syngene International | 6.21 | 51.54 | 11.05% | 4642 |
Sai Life Sciences | 7.45 | 92.18 | 10.96% | 1694 |
Cohan Lifesciences | 14.11 | 97.29 | 13.61% | 1197 |
Divi's Lab | 10.24 | 83.22 | 15.35% | 9360 |
Pre Issue Share Holding: 77.23%
Post Issue Share Holding: 74.68%
Anthem Biosciences
No. 49, F1 & F2, Canara Bank Road, Bommasandra Industrial Area, Phase 1, Bommasandra, Bengaluru, Karnataka, 560099Kfin Technologies Limited
Phone: 04067162222, 04079611000
Email: anthem.ipo@kfintech.com
Ans. Anthem Biosciences Limited IPO is a Mainboard IPO. The issue is priced at ₹540-570 per equity share. The minimum order quantity is 26 Shares. The IPO opens on Jul 14, 2025, and closes on Jul 16, 2025. Kfin Technologies Limited is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Ans. The Anthem Biosciences Limited IPO opens on Jul 14, 2025 and closes on Jul 16, 2025.
Ans. The size of Anthem Biosciences Limited IPO is OFS : 5,95,61,404 shares(aggregating up to ₹3395.00 Cr).
Ans. The IPO price band is set between ₹540-570 per equity share.
Ans. To apply for Anthem Biosciences Limited IPO IPO, follow the steps given below:
Ans. The share allotment date of Anthem Biosciences Limited IPO is Jul 17, 2025.
Ans. The Anthem Biosciences Limited IPO will be listed on Jul 21, 2025.
Ans. Follow the steps to check the allotment status for Anthem Biosciences Limited IPO here.
Offer Date | Jul 14 - Jul 16, 2025 |
Offer Price | ₹ 540-570 |
Lot Size | 26 |
Please login to Apply IPO